HSBC Holdings
ENTA icon

HSBC Holdings’s Enanta Pharmaceuticals ENTA Stock Holding History

HSBC Holdings’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-10,415
Closed -$124K – 3000
2025
Q3 		$124K Buy
10,415
+205
+2% +$1.64K ﹤0.01% 2571
2025
Q2 		$77K Sell
10,210
-7,363
-42% -$44.3K ﹤0.01% 2884
2025
Q1 		$94.8K Buy
17,573
+1,238
+8% +$7.65K ﹤0.01% 2813
2024
Q4 		$90.7K Sell
16,335
-200
-1% -$1.92K ﹤0.01% 2907
2024
Q3 		$166K Sell
16,535
-1,551
-9% -$20.3K ﹤0.01% 2685
2024
Q2 		$226K Sell
18,086
-2,303
-11% -$31.1K ﹤0.01% 2474
2024
Q1 		$356K Sell
20,389
-5,946
-23% -$78.7K ﹤0.01% 2316
2023
Q4 		$251K Buy
26,335
+15,949
+154% +$149K ﹤0.01% 2365
2023
Q3 		$115K Buy
+10,386
New +$167K ﹤0.01% 2534
2023
Q1 		– Sell
-7,144
Closed -$324K – 2777
2022
Q4 		$324K Buy
7,144
+1,402
+24% +$63.9K ﹤0.01% 2498
2022
Q3 		$302K Sell
5,742
-14,230
-71% -$831K ﹤0.01% 2414
2022
Q2 		$950K Sell
19,972
-352
-2% -$19.1K ﹤0.01% 1951
2022
Q1 		$1.47M Buy
20,324
+3,055
+18% +$199K ﹤0.01% 1746
2021
Q4 		$1.25M Buy
17,269
+5,365
+45% +$421K ﹤0.01% 1916
2021
Q3 		$681K Sell
11,904
-2
-0% -$99 ﹤0.01% 2079
2021
Q2 		$529K Buy
+11,906
New +$583K ﹤0.01% 2130
2021
Q1 		– Sell
-5,269
Closed -$218K – 2834
2020
Q4 		$218K Buy
5,269
+33
+0.6% +$1.45K ﹤0.01% 2758
2020
Q3 		$238K Sell
5,236
-15,059
-74% -$730K ﹤0.01% 2376
2020
Q2 		$1.02M Buy
+20,295
New +$1.05M ﹤0.01% 1437
2020
Q1 		– Sell
-14,740
Closed -$914K – 2782
2019
Q4 		$914K Buy
+14,740
New +$914K ﹤0.01% 1881

Other funds holding ENTA

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

HSBC Holdings's ENTA Position: Q4 2025 in Review

HSBC Holdings sold out of Enanta Pharmaceuticals (ENTA) in Q4 2025, closing a stake of 10,415 shares — an estimated $124K sold.

HSBC Holdings first reported a position in ENTA in Q4 2019 and held it in 20 quarters. The position peaked at $1.47M in Q1 2022. 132 funds tracked by Wall St. Rank hold ENTA as of Q4 2025.

  • HSBC Holdings reported no remaining Enanta Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • HSBC Holdings sold 10,415 Enanta Pharmaceuticals shares in Q4 2025, an estimated $124K.
  • HSBC Holdings first reported a position in Enanta Pharmaceuticals in Q4 2019 and held it in 20 quarters.
  • HSBC Holdings's Enanta Pharmaceuticals position peaked at $1.47M in Q1 2022.
  • 132 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q4 2025.

Based on HSBC Holdings's 13F filing for Q4 2025, filed 6 Mar 2026.